BPC-157 vs TB-500: Two Repair Peptides, Two Different Mechanisms

May 19, 2026 · 6 min read · Allen Biotechnology Co research desk

These two compounds are the most studied "repair" peptides in this literature and are often discussed as if interchangeable. Grouping them together, however, obscures how differently they act and why comparative and combination protocols exist.

Side by side

BPC-157TB-500 (Tβ4)
OriginSynthetic fragment based on a human gastric juice proteinSynthetic version of thymosin beta-4, a natural human peptide
Size15 amino acids (~1.4 kDa)43 amino acids (~4.9 kDa), or active fragment
Core mechanismCytoprotection, angiogenesis (VEGF), NO-system modulation, fibroblast migration via FAK–paxillinG-actin sequestration driving cell migration and differentiation
Signature modelsTendon/ligament transection, GI mucosal injury (rodent)Dermal wounds, corneal repair, cardiac injury (rodent; some human ophthalmic trials)
StabilityUnusually robust, acid-stableStandard peptide handling required
Human trialsNone publishedOphthalmic (Tβ4 eye drops) only

Why combination protocols use both

Combination protocols appear in the literature and in lab practice because the two peptides act at different layers of the repair cascade. TB-500's actin mechanism affects whether cells can move; migration into a wound bed is actin-dependent by definition. BPC-157's reported effects focus on the local environment those cells enter, including vascularization, growth-factor expression and cytoprotection. In vitro, the distinction maps to different assays: migration/scratch tests for TB-500, and angiogenesis and survival assays for BPC-157.

Which does a given protocol call for?

Full research summaries: BPC-157 overview · TB-500 overview. For research use only — not for human or veterinary use.

Independent testing standards with batch-matched documentation.

Allen Biotechnology Co publishes its testing policy, provides a labeled sample certificate, and offers direct research support.